Global Markets Direct’s, ‘Malaria – Pipeline Review, H1 2015′, provides an overview of the Malaria’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Malaria, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Malaria and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

• The report provides a snapshot of the global therapeutic landscape of Malaria
• The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in the therapeutics development for Malaria and enlists all their major and minor projects
• The report summarizes all the dormant and discontinued pipeline projects
• A review of the Malaria products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• A detailed assessment of monotherapy and combination therapy pipeline projects
• Coverage of the Malaria pipeline on the basis of target, MoA, route of administration and molecule type
• Latest news and deals relating related to pipeline products

Reasons to buy

• Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Develop strategic initiatives by understanding the focus areas of leading companies
• Identify and understand important and diverse types of therapeutics under development for Malaria
• Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
• Devise corrective measures for pipeline projects by understanding Malaria pipeline depth and focus of Indication therapeutics
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
• Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2
Introduction 6
Malaria Overview 7
Therapeutics Development 8
Malaria - Therapeutics under Development by Companies 10
Malaria - Therapeutics under Investigation by Universities/Institutes 17
Malaria - Pipeline Products Glance 22
Malaria - Products under Development by Companies 26
Malaria - Products under Investigation by Universities/Institutes 34
Malaria - Companies Involved in Therapeutics Development 40
Malaria - Therapeutics Assessment 107
Drug Profiles 118
Malaria - Recent Pipeline Updates 348
Malaria - Dormant Projects 367
Malaria - Discontinued Products 376
Malaria - Product Development Milestones 379
Appendix 388

List of Tables

Number of Products under Development for Malaria, H1 2015 29
Number of Products under Development for Malaria - Comparative Analysis, H1 2015 30
Number of Products under Development by Companies, H1 2015 32
Number of Products under Development by Companies, H1 2015 (Contd..1) 33
Number of Products under Development by Companies, H1 2015 (Contd..2) 34
Number of Products under Development by Companies, H1 2015 (Contd..3) 35
Number of Products under Development by Companies, H1 2015 (Contd..4) 36
Number of Products under Development by Companies, H1 2015 (Contd..5) 37
Number of Products under Investigation by Universities/Institutes, H1 2015 39
Number of Products under Investigation by Universities/Institutes, H1 2015 (Contd..1) 40
Number of Products under Investigation by Universities/Institutes, H1 2015 (Contd..2) 41
Number of Products under Investigation by Universities/Institutes, H1 2015 (Contd..3) 42
Comparative Analysis by Late Stage Development, H1 2015 43
Comparative Analysis by Clinical Stage Development, H1 2015 44
Comparative Analysis by Early Stage Development, H1 2015 45
Comparative Analysis by Unknown Stage Development, H1 2015 46
Products under Development by Companies, H1 2015 47
Products under Development by Companies, H1 2015 (Contd..1) 48
Products under Development by Companies, H1 2015 (Contd..2) 49
Products under Development by Companies, H1 2015 (Contd..3) 50
Products under Development by Companies, H1 2015 (Contd..4) 51
Products under Development by Companies, H1 2015 (Contd..5) 52
Products under Development by Companies, H1 2015 (Contd..6) 53
Products under Development by Companies, H1 2015 (Contd..7) 54
Products under Investigation by Universities/Institutes, H1 2015 55
Products under Investigation by Universities/Institutes, H1 2015 (Contd..1) 56
Products under Investigation by Universities/Institutes, H1 2015 (Contd..2) 57
Products under Investigation by Universities/Institutes, H1 2015 (Contd..3) 58
Products under Investigation by Universities/Institutes, H1 2015 (Contd..4) 59
Products under Investigation by Universities/Institutes, H1 2015 (Contd..5) 60
Malaria - Pipeline by 4SC AG, H1 2015 61
Malaria - Pipeline by Acetylon Pharmaceuticals, Inc., H1 2015 62
Malaria - Pipeline by Actelion Ltd, H1 2015 63
Malaria - Pipeline by Agilvax, Inc., H1 2015 64
Malaria - Pipeline by Akshaya Bio Inc., H1 2015 65
Malaria - Pipeline by Amura Holdings Limited, H1 2015 66
Malaria - Pipeline by Artificial Cell Technologies, Inc., H1 2015 67
Malaria - Pipeline by AstraZeneca Plc, H1 2015 68
Malaria - Pipeline by Bharat Biotech International Limited, H1 2015 69
Malaria - Pipeline by Callaghan Innovation Research Ltd., H1 2015 70
Malaria - Pipeline by Carna Biosciences, Inc., H1 2015 71
Malaria - Pipeline by CEL-SCI Corporation, H1 2015 72
Malaria - Pipeline by Celgene Corporation, H1 2015 73
Malaria - Pipeline by Cellceutix Corporation, H1 2015 74
Malaria - Pipeline by Chong Kun Dang Pharmaceutical Corp., H1 2015 75
Malaria - Pipeline by Cilian AG, H1 2015 76
Malaria - Pipeline by Clevexel Pharma SAS, H1 2015 77
Malaria - Pipeline by Daiichi Sankyo Company, Limited, H1 2015 78
Malaria - Pipeline by DesignMedix, Inc., H1 2015 79
Malaria - Pipeline by Eisai Co., Ltd., H1 2015 80
Malaria - Pipeline by Genocea Biosciences, Inc., H1 2015 81
Malaria - Pipeline by GenVec, Inc., H1 2015 82
Malaria - Pipeline by Genzyme Corporation, H1 2015 83
Malaria - Pipeline by Georgia Tech Research Corporation, H1 2015 84
Malaria - Pipeline by GlaxoSmithKline Plc, H1 2015 85
Malaria - Pipeline by Hawaii Biotech, Inc., H1 2015 86
Malaria - Pipeline by iBio, Inc., H1 2015 87
Malaria - Pipeline by Imaxio SA, H1 2015 88
Malaria - Pipeline by Immtech Pharmaceuticals, Inc., H1 2015 89
Malaria - Pipeline by Immunitor, Inc., H1 2015 90
Malaria - Pipeline by Immunovaccine, Inc., H1 2015 91
Malaria - Pipeline by Inovio Pharmaceuticals, Inc., H1 2015 92
Malaria - Pipeline by IPCA Laboratories Limited, H1 2015 93
Malaria - Pipeline by iQur Limited, H1 2015 94
Malaria - Pipeline by IRBM Science Park SpA, H1 2015 95
Malaria - Pipeline by iThemba Pharmaceuticals (Pty) Ltd., H1 2015 96
Malaria - Pipeline by Jenrin Discovery, Inc., H1 2015 97
Malaria - Pipeline by Jomaa Pharma GmbH, H1 2015 98
Malaria - Pipeline by KAEL-GemVax Co., Ltd., H1 2015 99
Malaria - Pipeline by Kancera AB, H1 2015 100
Malaria - Pipeline by Lipotek Pty Ltd., H1 2015 101
Malaria - Pipeline by LondonPharma Ltd, H1 2015 102
Malaria - Pipeline by Merck KGaA, H1 2015 103
Malaria - Pipeline by MerLion Pharmaceuticals Pte Ltd, H1 2015 104
Malaria - Pipeline by Microbiotix, Inc., H1 2015 105
Malaria - Pipeline by Molplex Ltd., H1 2015 106
Malaria - Pipeline by Mucosis B.V., H1 2015 107
Malaria - Pipeline by Mymetics Corporation, H1 2015 108
Malaria - Pipeline by Novartis AG, H1 2015 109
Malaria - Pipeline by Panacela Labs, Inc., H1 2015 110
Malaria - Pipeline by PaxVax, H1 2015 111
Malaria - Pipeline by Pfenex Inc., H1 2015 112
Malaria - Pipeline by Pfizer Inc., H1 2015 113
Malaria - Pipeline by Raptor Pharmaceuticals Corp., H1 2015 114
Malaria - Pipeline by Rodos BioTarget GmbH, H1 2015 115
Malaria - Pipeline by Sanaria Inc., H1 2015 116
Malaria - Pipeline by Sanofi, H1 2015 117
Malaria - Pipeline by SATT Lutech SAS, H1 2015 118
Malaria - Pipeline by SEEK Group, H1 2015 119
Malaria - Pipeline by Selecta Biosciences, Inc., H1 2015 120
Malaria - Pipeline by Sigma-Tau Pharmaceuticals, Inc, H1 2015 121
Malaria - Pipeline by Sigma-Tau S.p.A., H1 2015 122
Malaria - Pipeline by Takeda Pharmaceutical Company Limited, H1 2015 123
Malaria - Pipeline by Telormedix SA, H1 2015 124
Malaria - Pipeline by Vaccibody AS, H1 2015 125
Malaria - Pipeline by VLP Biotech, Inc., H1 2015 126
Malaria - Pipeline by Zydus Cadila Healthcare Limited, H1 2015 127
Assessment by Monotherapy Products, H1 2015 128
Assessment by Combination Products, H1 2015 129
Number of Products by Stage and Target, H1 2015 131
Number of Products by Stage and Mechanism of Action, H1 2015 134
Number of Products by Stage and Route of Administration, H1 2015 136
Number of Products by Stage and Molecule Type, H1 2015 138
Malaria Therapeutics - Recent Pipeline Updates, H1 2015 369
Malaria - Dormant Projects, H1 2015 388
Malaria - Dormant Projects (Contd..1), H1 2015 389
Malaria - Dormant Projects (Contd..2), H1 2015 390
Malaria - Dormant Projects (Contd..3), H1 2015 391
Malaria - Dormant Projects (Contd..4), H1 2015 392
Malaria - Dormant Projects (Contd..5), H1 2015 393
Malaria - Dormant Projects (Contd..6), H1 2015 394
Malaria - Dormant Projects (Contd..7), H1 2015 395
Malaria - Dormant Projects (Contd..8), H1 2015 396
Malaria - Discontinued Products, H1 2015 397
Malaria - Discontinued Products (Contd..1), H1 2015 398
Malaria - Discontinued Products (Contd..2), H1 2015 399

List of Figures

Number of Products under Development for Malaria, H1 2015 29
Number of Products under Development for Malaria - Comparative Analysis, H1 2015 30
Number of Products under Development by Companies, H1 2015 31
Number of Products under Investigation by Universities/Institutes, H1 2015 38
Comparative Analysis by Late Stage Development, H1 2015 43
Comparative Analysis by Clinical Stage Development, H1 2015 44
Comparative Analysis by Early Stage Products, H1 2015 45
Comparative Analysis by Unknown Stage Development, H1 2015 46
Assessment by Monotherapy Products, H1 2015 128
Number of Products by Top 10 Targets, H1 2015 130
Number of Products by Stage and Top 10 Targets, H1 2015 130
Number of Products by Top 10 Mechanism of Actions, H1 2015 133
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 133
Number of Products by Top 10 Routes of Administration, H1 2015 135
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 135
Number of Products by Top 10 Molecule Types, H1 2015 137
Number of Products by Stage and Top 10 Molecule Types, H1 2015 137